- Convergent Therapeutics and NorthStar Medical Radioisotopes have expanded their agreement to co-locate dedicated manufacturing suites at NorthStar’s Beloit, Wisconsin campus.
- The arrangement is intended to secure Ac-225 supply and support clinical batch production of CONV01-α through to commercial manufacturing.
Convergent Therapeutics Inc. and NorthStar Medical Radioisotopes have announced an expanded agreement under which Convergent will support its drug development and clinical batch production using dedicated manufacturing suites at NorthStar’s Beloit, Wisconsin campus. The companies said the co-location is designed to establish an integrated supply chain for CONV01-α drug product production using Actinium-225 (Ac-225).
According to the announcement, locating Convergent’s manufacturing activities at NorthStar is intended to relieve supply constraints associated with alpha-emitting radiotherapies. The arrangement is expected to support Convergent’s ongoing clinical trials through to commercial production by providing reliable access to Ac-225 and aligned manufacturing infrastructure.
“The relationship with NorthStar enables us to fully realize the potential of our leading radioantibody program as we demonstrate the advantages of alpha emitters in addressing metastatic castration-resistant prostate cancer (mCRPC) and the significant need for new, safer, and more effective therapies for patients.”
Philip Kantoff, M.D., CEO and Co-Founder of Convergent Therapeutics
CONV01-α is Convergent’s lead programme for mCRPC and other radiopharmaceuticals in its pipeline. The company stated that reliable Ac-225 supply supports its ability to advance alpha-based radiotherapies, building on clinical data generated to date with CONV01-α. NorthStar recently confirmed it produces alpha radioisotopes for therapeutic applications at scale, with Convergent identified as a key customer for Ac-225.
The expanded agreement builds on a strategic contract manufacturing services agreement announced in August 2024. Under that earlier arrangement, NorthStar agreed to supply Ac-225 and use its contract development and manufacturing facility to manufacture CONV01-α for Convergent’s clinical trials, reinforcing NorthStar’s role as a CDMO and provider of contract manufacturing services for radiopharmaceutical development.
